Mirtazapina Ratiopharm (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine. It also antagonizes specific serotonin receptors (5‑HT2 and 5‑HT3) and histamine H1 receptors, leading to enhanced serotonergic and noradrenergic neurotransmission that contributes to its antidepressant effect.

The appropriate dose of Mirtazapina Ratiopharm is determined individually by a qualified prescriber based on the patient’s clinical condition, response to therapy, and tolerability. Dosage adjustments are made according to professional medical guidance.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. Healthcare providers should weigh potential benefits against possible risks and consider alternative treatments when treating pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from selective serotonin reuptake inhibitors (SSRIs) by its combined noradrenergic and serotonergic activity and strong antihistamine effect. This profile often results in pronounced sedation and weight gain, which can be advantageous for patients with insomnia but may be less desirable for those concerned about metabolic effects.

Mirtazapina Ratiopharm tablets should be stored at temperatures below 25 °C, in their original container, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use after the expiry date printed on the packaging.

The medication is taken orally, typically once daily in the evening, to take advantage of its sedative properties. It can be swallowed whole with water; sublingual or buccal administration is also possible if recommended by the prescriber.

Serious risks include agranulocytosis, severe neutropenia, hepatotoxicity, seizures, hyponatremia (especially in the elderly), and the emergence or worsening of suicidal thoughts. Patients should be monitored closely for any of these conditions, and treatment should be discontinued if they occur.

Mirtazapina Ratiopharm is contraindicated in individuals with known hypersensitivity to mirtazapine or any excipients, and in patients currently taking monoamine oxidase inhibitors (MAOIs) or who have used an MAOI within the past 14 days. Caution is also advised for patients with severe hepatic impairment.